399 related articles for article (PubMed ID: 34540900)
21. BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.
Borck PC; Guo LW; Plutzky J
Circ Res; 2020 Apr; 126(9):1190-1208. PubMed ID: 32324495
[TBL] [Abstract][Full Text] [Related]
22. BET proteins: Biological functions and therapeutic interventions.
Guo J; Zheng Q; Peng Y
Pharmacol Ther; 2023 Mar; 243():108354. PubMed ID: 36739915
[TBL] [Abstract][Full Text] [Related]
23. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.
Padmanabhan B; Mathur S; Manjula R; Tripathi S
J Biosci; 2016 Jun; 41(2):295-311. PubMed ID: 27240990
[TBL] [Abstract][Full Text] [Related]
24. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
[TBL] [Abstract][Full Text] [Related]
25. Alternative Mechanisms for DNA Engagement by BET Bromodomain-Containing Proteins.
Kalra P; Zahid H; Ayoub A; Dou Y; Pomerantz WCK
Biochemistry; 2022 Jul; 61(13):1260-1272. PubMed ID: 35748495
[TBL] [Abstract][Full Text] [Related]
26. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.
Miller TC; Simon B; Rybin V; Grötsch H; Curtet S; Khochbin S; Carlomagno T; Müller CW
Nat Commun; 2016 Dec; 7():13855. PubMed ID: 27991587
[TBL] [Abstract][Full Text] [Related]
27. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
[TBL] [Abstract][Full Text] [Related]
28. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
Olp MD; Zhu N; Smith BC
Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
[TBL] [Abstract][Full Text] [Related]
29. Emerging roles of BET proteins in transcription and co-transcriptional RNA processing.
Eischer N; Arnold M; Mayer A
Wiley Interdiscip Rev RNA; 2023 Jan; 14(1):e1734. PubMed ID: 35491403
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A; Caputo V; Karadimitris A
Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
[TBL] [Abstract][Full Text] [Related]
31. Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression.
Michaeloudes C; Mercado N; Clarke C; Bhavsar PK; Adcock IM; Barnes PJ; Chung KF
J Immunol; 2014 May; 192(10):4913-4920. PubMed ID: 24733848
[TBL] [Abstract][Full Text] [Related]
32. BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.
Deeney JT; Belkina AC; Shirihai OS; Corkey BE; Denis GV
PLoS One; 2016; 11(3):e0151329. PubMed ID: 27008626
[TBL] [Abstract][Full Text] [Related]
33. Identification of unique, differentiation stage-specific patterns of expression of the bromodomain-containing genes Brd2, Brd3, Brd4, and Brdt in the mouse testis.
Shang E; Salazar G; Crowley TE; Wang X; Lopez RA; Wang X; Wolgemuth DJ
Gene Expr Patterns; 2004 Sep; 4(5):513-9. PubMed ID: 15261828
[TBL] [Abstract][Full Text] [Related]
34. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
[TBL] [Abstract][Full Text] [Related]
35. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
[TBL] [Abstract][Full Text] [Related]
36. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
37. Optimization of a "bump-and-hole" approach to allele-selective BET bromodomain inhibition.
Runcie AC; Zengerle M; Chan KH; Testa A; van Beurden L; Baud MGJ; Epemolu O; Ellis LCJ; Read KD; Coulthard V; Brien A; Ciulli A
Chem Sci; 2018 Mar; 9(9):2452-2468. PubMed ID: 29732121
[TBL] [Abstract][Full Text] [Related]
38. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.
Roberts TC; Etxaniz U; Dall'Agnese A; Wu SY; Chiang CM; Brennan PE; Wood MJA; Puri PL
Sci Rep; 2017 Jul; 7(1):6153. PubMed ID: 28733670
[TBL] [Abstract][Full Text] [Related]
39. BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer.
Hajmirza A; Emadali A; Gauthier A; Casasnovas O; Gressin R; Callanan MB
Biomedicines; 2018 Feb; 6(1):. PubMed ID: 29415456
[TBL] [Abstract][Full Text] [Related]
40. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
